ImmunID to Collaborate with IRX Therapeutics on Test to Predict Immunotherapy Response | GenomeWeb

NEW YORK (GenomeWeb) – ImmunID announced today that it is working with IRX Therapeutics, a clinical-stage cancer immunotherapy developer, to predict response to IRX's investigational drug IRX-2.

Under the terms of the collaboration, ImmunID will use its ImmunTracker technology to assess the immune-modulatory effect of IRX-2 in a randomized phase 2b study of patients with newly diagnosed head and neck squamous cell cancer. The trial is designed to determine whether neoadjuvant treatment with IRX-2 — before an attempt at curative surgery — can reduce the risk of later recurrence.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.

Research funding in Canada is to remain mostly the same, ScienceInsider reports.

In Science this week: random DNA replication errors play role in cancer, and more.

The Bill and Melinda Gates Foundation embarks on an open-access publishing path.

Mar
28
Sponsored by
Illumina

This webinar describes the optimization and validation of two commercially available next-generation sequencing assays that may be used to guide personalized cancer treatment. 

Apr
11
Sponsored by
Personal Genome Diagnostics

This webinar will provide an overview of genomic alterations that play a role in immunotherapy response.

May
04
Sponsored by
Qiagen

This online seminar will provide an overview of the use of liquid biopsies for cancer recurrence monitoring with a particular focus on colorectal cancer.

May
23
Sponsored by
Agilent Technologies

This webinar will discuss a target enrichment workflow for high-confidence detection of variants.